{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "12757028", "DateCompleted": {"Year": "2003", "Month": "08", "Day": "22"}, "DateRevised": {"Year": "2019", "Month": "10", "Day": "25"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0391-3988", "JournalIssue": {"Volume": "26", "Issue": "4", "PubDate": {"Year": "2003", "Month": "Apr"}}, "Title": "The International journal of artificial organs", "ISOAbbreviation": "Int J Artif Organs"}, "ArticleTitle": "The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs.", "Pagination": {"StartPage": "297", "EndPage": "303", "MedlinePgn": "297-303"}, "Abstract": {"AbstractText": ["Ozonated autohemotherapy is used as a complementary medical approach in the treatment of vascular disorders. One of the greatest problems concerning an application of ozone in medicine is its induction of oxidative stress. The standards of ozonotherapy were elaborated recently making this treatment useful and probably non toxic. The aim of the present study was to investigate the influence of ozonated autohemotherapy on the oxidative stress extent in hemodialyzed patients, known to be particularly exposed to generation and deleterious effects of free radicals. Twelve continuously hemodialyzed subjects with atherosclerotic ischemia of the lower limbs were examined in a prospective, controlled, single blind study. Autohemotherapy with blood exposure to oxygen served as a control. The protein and lipid peroxidation products, the reduced glutathione level in red blood cells and free hemoglobin plasma concentration were measured. The study showed that ozonated autohemotherapy with ozone concentration 50 microg/ml per gram of blood induced a significant decrease in glutathione level after 9 sessions of this procedure. Therapy did not cause either the enhancement of protein and lipid peroxidation, or erythrocytes damage. It seems likely that the antioxidant defense system, part of which is glutathione, neutralizes oxidative properties of ozone in this concentration and protects against oxidative cell damage."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk, Gdansk, Poland. leszek.tylicki@wp.pl"}], "Identifier": [], "LastName": "Tylicki", "ForeName": "L", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Nieweglowski", "ForeName": "T", "Initials": "T"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Biedunkiewicz", "ForeName": "B", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chamienia", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Debska-Slizien", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Aleksandrowicz", "ForeName": "E", "Initials": "E"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lysiak-Szydlowska", "ForeName": "W", "Initials": "W"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Rutkowski", "ForeName": "B", "Initials": "B"}], "PublicationTypeList": ["Clinical Trial", "Controlled Clinical Trial", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Int J Artif Organs", "NlmUniqueID": "7802649", "ISSNLinking": "0391-3988"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Hemoglobins"}, {"RegistryNumber": "0", "NameOfSubstance": "Oxidants, Photochemical"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "GAN16C9B8O", "NameOfSubstance": "Glutathione"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["blood", "drug therapy", "etiology"], "DescriptorName": "Arteriosclerosis"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": ["chemistry", "drug effects"], "DescriptorName": "Erythrocytes"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["blood"], "DescriptorName": "Glutathione"}, {"QualifierName": ["analysis"], "DescriptorName": "Hemoglobins"}, {"QualifierName": ["drug effects"], "DescriptorName": "Hemolysis"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["blood", "drug therapy", "etiology"], "DescriptorName": "Ischemia"}, {"QualifierName": ["blood", "complications", "therapy"], "DescriptorName": "Kidney Failure, Chronic"}, {"QualifierName": ["blood supply"], "DescriptorName": "Leg"}, {"QualifierName": ["drug effects"], "DescriptorName": "Lipid Peroxidation"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Oxidants, Photochemical"}, {"QualifierName": ["drug effects"], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Renal Dialysis"}, {"QualifierName": [], "DescriptorName": "Single-Blind Method"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2003", "Month": "5", "Day": "22", "Hour": "5", "Minute": "0"}, {"Year": "2003", "Month": "8", "Day": "23", "Hour": "5", "Minute": "0"}, {"Year": "2003", "Month": "5", "Day": "22", "Hour": "5", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["12757028", "10.1177/039139880302600404"]}}], "PubmedBookArticle": []}